Abstract
Philip Morris International will release its second-quarter 2026 results on July 22, 2026 Pre-MKt; this preview outlines last quarter’s performance, current-quarter forecasts, and key analyst perspectives to frame revenue, margins, earnings, and the near-term impact of smoke-free initiatives including ZYN and IQOS.Market Forecast
For the current quarter, market expectations point to revenue of 10.64 billion US dollars, implying 3.01% year-over-year growth, with estimated EBIT of 4.41 billion US dollars (+6.38% YoY) and adjusted EPS of 2.03 (+9.39% YoY). Forecasts do not specify gross or net margin, but directionally imply modest revenue growth and faster earnings expansion on mix and efficiency.The main business is centered on smoke-free products paired with combustible tobacco, with the former expected to remain the core growth engine as new products and regulatory milestones mature through 2026. The most promising segment is smoke-free: it generated 5.77 billion US dollars last quarter, and in 2025 the company’s smoke-free net revenue grew 15.00% year over year; within that, nicotine pouches saw shipment growth of roughly 37% in the United States and above 35% internationally, and 20 ZYN variants recently received Modified Risk Tobacco Product orders.
Last Quarter Review
Philip Morris International reported revenue of 10.15 billion US dollars (+9.09% YoY) for the prior quarter, with a gross profit margin of 68.06%, GAAP net profit attributable to the parent of 2.44 billion US dollars, a net profit margin of 24.03%, and adjusted EPS of 1.96 (+15.98% YoY).A notable financial highlight was the sequential acceleration in bottom line: net profit rose by 13.87% quarter over quarter, supported by scale and mix. Main business revenue composition underscored the company’s transition: smoke-free products delivered 5.77 billion US dollars while combustible tobacco contributed 4.38 billion US dollars; more broadly, the smoke-free portfolio’s 2025 net revenue growth of 15.00% YoY suggests continued momentum into 2026.
Current Quarter Outlook
Smoke-Free Portfolio Momentum and Margin Trajectory
Smoke-free products remain the central catalyst this quarter, driven by IQOS and the oral nicotine portfolio. The current-quarter EPS estimate of 2.03, up 9.39% year over year, alongside an EBIT growth outlook of 6.38%, implies operating leverage from scaling smoke-free volumes and mix across geographies. Management’s execution track record in IQOS expansions and the broadening of the device and consumable ecosystem supports sustainable revenue quality even as certain markets face taxation or consumer price sensitivity. Given the prior quarter’s gross margin baseline of 68.06%, incremental margin variability this quarter will likely be dictated by category mix between heated tobacco units, oral nicotine pouches, and combustibles, as well as price realization in core markets.The resilience of IQOS following tax-driven price actions in Japan is an incremental positive for the quarter’s run-rate. Recent commentary highlighted that IQOS maintained share despite a significant excise-tax-driven price increase on April 1, which suggests pricing latitude and brand equity that can cushion near-term volatility. As the company advances the rollout of IQOS ILUMA in additional markets, ramp dynamics could skew toward upfront marketing and channel costs; however, the EBIT forecast still implies positive operating momentum. On balance, smoke-free’s combination of volume growth, pricing power, and ongoing device-user conversion should continue to anchor earnings expansion in the second quarter.
ZYN and Oral Nicotine: Regulatory Tailwinds and Scale-Up
The oral nicotine franchise—particularly ZYN—appears poised for outsized attention this quarter following Modified Risk Tobacco Product orders granted for 20 ZYN variants. This authorization allows the company to communicate specific reduced-risk claims relative to cigarette use, which can unlock incremental demand channels and strengthen brand positioning in adult nicotine alternatives. Additionally, the planned US launch scale of Zyn Ultra, with higher milligram strengths across flavors aligned to existing offerings, adds a new tier of product differentiation; analysts have framed this as a near-term stock catalyst and a medium-term growth driver.From a financial standpoint, ZYN’s trajectory should support both top-line growth and mixed effects on margins as marketing and distribution investments scale to match demand. In 2025, the nicotine pouch category within the company experienced robust shipment growth—nearly 37% in the United States and above 35% internationally—setting a high base for the current year; translating that into revenue growth hinges on distribution breadth, consumer switching, and sustained regulatory clarity. The Modified Risk orders, combined with strengthened US enforcement frameworks on foreign tobacco product registrations proposed by the FDA, can level the competitive field, potentially favoring established players in compliant categories. Execution risks remain centered on ensuring supply, calibrating promotions, and managing costs during ramp, but the unit economics at scale and brand momentum support the current quarter’s revenue and EBIT estimates.
Combustible Business Stability and Cash Discipline
Combustible tobacco continues to provide cash flow and price support that helps fund transformation initiatives. Last quarter, combustibles accounted for 4.38 billion US dollars in revenue, a meaningful base that can smooth volatility from newer categories. While the company’s multi-year strategy emphasizes transitioning adult smokers to smoke-free alternatives, pricing discipline and portfolio management in combustibles remain valuable levers for maintaining aggregate margin quality, especially in markets where device adoption curves vary by income levels and regulatory environments.This quarter’s net profit and EPS forecasts imply ongoing expense discipline and measured reinvestment. The prepayment of approximately 1.10 billion US dollars on a five-year term loan by late June underscores a continued focus on balance sheet optimization amid a changing rate environment. That action should reduce interest expense run-rate over time and improve financial flexibility for reinvestment or shareholder returns. The recurring dividend cadence, reaffirmed in June at 1.47 US dollars per share on a quarterly basis, supports a consistent capital return framework that accompanies transformation spending—an equilibrium that should feature in investor interpretation of second-quarter cash generation and outlook commentary.
Regulatory, Governance, and One-Offs: What Can Sway the Print
Regulatory items may influence sentiment around the Q2 report and guidance color. The Modified Risk Tobacco Product orders for ZYN variants are a clear positive, enabling more informative marketing in the United States that could accelerate consumer switching. At the same time, a recent 7 million euro penalty in Italy for smoke-free marketing language reflects the complexity of communications across jurisdictions; while financially immaterial in isolation, such actions can shape messaging strategies and near-term marketing execution. The company’s full-year guidance framework already contemplates a range of regulatory scenarios, but investors will watch for any shifts in cost allocation toward compliance and consumer education.Leadership transitions also draw attention. The appointment of Massimo Andolina as Group Chief Financial Officer, effective August 1, 2026, has prompted scrutiny of continuity in financial strategy and investment pacing. The company’s communication around the transition, alongside recent debt prepayment, should reassure on funding discipline through the second half. One-offs remain part of the backdrop: the earlier announced non-cash impairment related to a Canadian affiliate affected full-year EPS guidance ranges but does not alter underlying operating trends for the second quarter; markets will look for management’s Q2 commentary to reaffirm that message.
Analyst Opinions
Bullish views dominate recent coverage. Across our screened items from January 1, 2026 through July 15, 2026, at least eight prominent institutions reiterated Buy ratings and none issued explicit Sell calls, resulting in an approximately 100% bullish skew over the period. Specific examples include Goldman Sachs, where Bonnie Herzog reiterated a Buy rating with a 205 US dollars price target; Barclays, where Pallav Mittal maintained Buy and, in multiple notes, set targets up to 205 US dollars; Morgan Stanley, where Eric Serotta reiterated Buy with a 205 US dollars target; and Stifel Nicolaus, where Matthew Smith maintained Buy with a 195 US dollars target. In addition, a broker upgrade during the period and multiple positive rating reiterations coincided with notable regulatory tailwinds for ZYN and ongoing momentum in smoke-free categories.Analysts consistently cite three pillars underpinning their constructive stance into the quarter. First, smoke-free momentum remains intact: IQOS maintained share in Japan despite an April excise-tax-driven price increase, indicating pricing power and customer retention that help support EBIT growth. Second, the ZYN franchise is receiving both product and regulatory catalysts: the US introduction of Zyn Ultra in higher strengths and the award of Modified Risk Tobacco Product orders for 20 ZYN variants give the company more latitude to communicate relative risk compared with cigarettes, potentially accelerating trial and adoption. Third, capital discipline is visible: the early repayment of approximately 1.10 billion US dollars on a term loan signals a commitment to interest expense reduction and flexibility for further investment, while routine dividends reinforce a balanced capital allocation.
Against that backdrop, the current quarter’s numerical setup is viewed as favorable. The revenue estimate of 10.64 billion US dollars (+3.01% YoY) is paired with an EPS estimate of 2.03 (+9.39% YoY) and EBIT of 4.41 billion US dollars (+6.38% YoY), a pattern that suggests operational efficiency and positive mix from smoke-free categories outweigh cost headwinds. Several institutions emphasize that near-term operating expenses—particularly for device rollouts, pouch distribution, and marketing—are investments into durable growth and brand equity; they argue that quarter-to-quarter margin fluctuations should be evaluated in the context of accelerating conversion from combustible products to smoke-free alternatives. The majority view expects continued top-line resilience and incremental margin improvement as smoke-free scales, with the possibility of further upside as IQOS ILUMA expands into new markets and ZYN Ultra builds US shelf presence.
Analysts acknowledge areas requiring monitoring, though these do not shift the broadly positive stance. Regulatory communications in the European Union, illustrated by the Italian fine, necessitate careful alignment of marketing claims, but the company’s global compliance infrastructure and recent US regulatory achievements suggest capacity to navigate jurisdictional nuance. Leadership transition to a new CFO in early August is regarded as a governance event to watch rather than a strategic pivot; continuity is inferred from the internal appointment and the company’s reiterated long-term targets. The earlier non-cash impairment associated with a Canadian affiliate adjusted full-year EPS ranges but is not expected to overshadow the second quarter’s operating print; analysts are focused on core earnings quality, smoke-free mix, and cash conversion.
Netting these views, the majority opinion into July 22, 2026 Pre-MKt anchors on a constructive outlook: smoke-free revenue and earnings leverage remain the central narrative; ZYN’s regulatory and product catalysts can add incremental growth; IQOS’ stability post-pricing actions supports category economics; and balance sheet moves indicate prudent financial stewardship. The anticipated 3.01% year-over-year revenue increase, coupled with mid-to-high single-digit EBIT growth and high single-digit EPS expansion, frames a setup that most institutions see as achievable or beatable depending on the pace of ZYN adoption and the phasing of smoke-free investments within the quarter. Investors will likely focus on management’s color around US ZYN distribution, IQOS user acquisition and retention trends, second-half reinvestment cadence, and any updates to the full-year outlook consistent with multi-year targets shared earlier in the year.
Comments